The impact of treatment-resistant depression on health care utilization and costs.
about
Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a reviewEfficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysisCharacterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims databaseCritical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adultsUse of cortical stimulation in neuropathic pain, tinnitus, depression, and movement disorders.Prevalence of treatment-resistant depression in primary care: cross-sectional data.Antidepressant use in suicides: a case-control study from the Friuli Venezia Giulia Region, Italy, 2005-2014.Antidepressant adherence after psychiatric hospitalization among VA patients with depression.Deep brain stimulation for treatment-resistant depression.Burden of illness in bipolar depression.Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in miceThe role of ketamine in treatment-resistant depression: a systematic review.Recurrence of sickness absence due to common mental disorders.Electroconvulsive therapy for major depression within the Veterans Health Administration.An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depressionNumber of risk genotypes is a risk factor for major depressive disorder: a case control study.Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorderCurrent perspectives in the management of treatment-resistant depression.Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression.Advances in the Management of Treatment-Resistant DepressionA comparison of the familiality of chronic depression in recurrent early-onset depression pedigrees using different definitions of chronicity.Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy.Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.Changes in self-reported HIV testing during South Africa's 2010/2011 national testing campaign: gains and shortfalls.Interaction between the MTHFR C677T polymorphism and traumatic childhood events predicts depression.Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studiesAntidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission.The long-term course of depression: development of an empirical index and identification of early adult outcomes.Predictors of repeated sick leave in the workplace because of mental disorders.High dosage of hypnotics predicts subsequent sleep-related breathing disorders and is associated with worse outcomes for depression.What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment.Sex differences in frequent ED use among those with multimorbid chronic diseases.Ketamine: stimulating antidepressant treatment?Depressive symptoms in elderly participants of an open university for elderly.Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study.Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.
P2860
Q24594131-11ABC525-6E0E-4F55-8912-F227AAAD9088Q26828452-DB3A56EF-4349-489D-BDE9-5E73BED56DD1Q28534539-B8041353-5371-42D1-BFC7-F70F945328B7Q28764080-D55D5281-6BE2-48E2-9841-A65B38761823Q30585843-238B2CA1-575C-49B1-BF8A-B46598845DF9Q30718433-6F7AECD5-9B3E-4331-B38D-A774E1A7B7A0Q33841870-4A09199B-CA8F-470A-9E3D-486F87F45F0FQ34135716-65B29544-3371-4A8A-B791-7A4E678062EFQ34153354-6B74795D-CC25-48CF-B00A-931471834FABQ34248110-8C669B31-6A84-4F66-9219-CA42E7A597C7Q34393030-F8DB26F5-EF0D-48E9-8DEA-7764E92CF7A5Q34436340-EF514B24-45B1-4BB3-A8C4-48D944193BE2Q34449588-0ABA19FB-9281-44E4-B616-43674867BFE5Q34486789-86173A30-806C-4A5D-B1F1-2588AA3A1497Q34490228-BD9F504E-94E0-4C9B-B343-84269841A1F5Q34642676-A1050CD7-9D14-4CA9-9993-BF028378BE42Q34893998-A4DC06BE-22A0-4B54-AC91-03254BB30C78Q35006487-AE3FC22B-A54A-47C9-8B2D-709B568EB419Q35205431-55AA6F36-5482-4BED-AB73-C6E91B9DC67BQ35236749-9FABF4C2-1EAD-4458-A1AA-767B7BA6DCE2Q35580388-B86BE449-F88B-42FF-9DC8-453968741D74Q35580600-EFAB2E61-73F3-4EFC-8D84-1BEF446EB788Q35944527-CDD8953D-7374-4492-BF53-286D886A5BE4Q36501706-FF66213F-A35C-489D-8848-549D1B9EAAE3Q36558223-8225B3D6-E4B7-4387-B694-5F35349783E8Q36588685-1746A258-DB38-49C2-8186-F6232B2F96F6Q36792622-0408CEBF-BCAC-447E-9A5A-E4FA82900543Q37065298-42B149CC-C536-4305-A22E-66B3585FCA69Q37114639-F1C7F149-682C-4192-95C2-B142EF70C46AQ37286014-0DA6611B-21AF-4E59-B408-4BF50EF35A5AQ37347988-E3144F0F-9B45-4FFF-ADAD-2967F2F30C40Q37562211-1CC01F35-69D8-461F-8E27-40F5D97D4D98Q37637187-E84605D9-2463-4F6F-B128-99BD424E3B87Q37715559-620C136B-9F60-4BE1-8B1A-57F65C05331DQ38824523-BD9CC7E4-5049-4630-BAAB-00F30DA1E162Q42338351-CD5B962C-193D-4194-B69D-7A3825F0AB42Q46748044-46C06260-74F6-448F-92D6-F07B3E811E01Q46850739-3D25E9E3-2CC7-49B3-9F0B-64F594CE3A74Q47399076-0F9F8A1D-49DF-4DFA-A51E-BD42A9ADE6B9Q55132660-AF89C5B2-14A9-4795-8F85-E45BCD467F96
P2860
The impact of treatment-resistant depression on health care utilization and costs.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The impact of treatment-resistant depression on health care utilization and costs.
@ast
The impact of treatment-resistant depression on health care utilization and costs.
@en
type
label
The impact of treatment-resistant depression on health care utilization and costs.
@ast
The impact of treatment-resistant depression on health care utilization and costs.
@en
prefLabel
The impact of treatment-resistant depression on health care utilization and costs.
@ast
The impact of treatment-resistant depression on health care utilization and costs.
@en
P2093
P1476
The impact of treatment-resistant depression on health care utilization and costs.
@en
P2093
A John Rush
Amy W Poret
Davina Ling
Ernst R Berndt
James M Russell
Stan Finkelstein
William H Crown
P304
P577
2002-11-01T00:00:00Z